Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
South Korea
· Delayed Price · Currency is KRW 28,950
-450 (-1.53%)
Mar 9, 2026, 3:30 PM KST
Daihan Pharmaceutical Revenue
Daihan Pharmaceutical had revenue of 56.17B KRW in the quarter ending September 30, 2025, with 2.42% growth. This brings the company's revenue in the last twelve months to 209.00B, up 3.48% year-over-year. In the year 2024, Daihan Pharmaceutical had annual revenue of 204.19B with 4.23% growth.
Revenue (ttm)
209.00B
Revenue Growth
+3.48%
P/S Ratio
0.81
Revenue / Employee
377.94M
Employees
553
Market Cap
170.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 204.19B | 8.28B | 4.23% |
| Dec 31, 2023 | 195.91B | 11.64B | 6.32% |
| Dec 31, 2022 | 184.27B | 12.80B | 7.47% |
| Dec 31, 2021 | 171.46B | 5.38B | 3.24% |
| Dec 31, 2020 | 166.08B | -2.68B | -1.59% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hana Pharm | 139.33B |
| Dongwha Pharm.Co.,Ltd | 493.33B |
| SAMSUNG PHARM. Co., LTD. | 44.29B |
| Ilsung Is | 66.51B |
| Whan In Pharm | 256.32B |
| REYON Pharmaceutical | 149.34B |
| AptaBio Therapeutics | 3.44B |
| JW Lifescience | 248.30B |